« Previous Release | Next Release »

May 9, 2012

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for 1st Quarter 2012

PDF File Size  
PDF Download pdf 244.7 KB Add to Briefcase

Investor service announcement no. 1/2012

 

To: NASDAQ OMX Copenhagen                                  Hørsholm, Denmark, May 9, 2012

 

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for 1st Quarter 2012 — results from January 1 to March 31, 2012

 

Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for 1st Quarter 2012 on Tuesday May 15, 2012 after 05:00 PM. Veloxis' Management will host an accompanying conference call to discuss the financial results on Wednesday May 16, 2012 at 03:00 PM CET (Denmark); 02:00 PM GMT (London); 09:00 AM ET (New York) and 06:00 AM PT (San Francisco). 

 

To access the live conference call, please dial one of the following numbers:

+45 32 72 76 25            Denmark Local

+1 631 510 7498           USA Local

+44 (0)1452 555 566     UK Local

Conference ID: 77202811

 

An audio cast of the conference will be available on www.veloxis.com.

 

For more information, please contact:

John Weinberg, M.D.
SVP, Commercial Operations & Investor Relations
Tlf: +1 908 304 3389
Email: jdw@veloxis.com
 		 Johnny Stilou
Chief Financial Officer
Tlf: +45 21 227 227
Email: jst@veloxis.com

 

Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

 

For further information, please visit www.veloxis.com.

 

 


Close window | Back to top


Copyright 2013 Veloxis Pharmaceuticals A/S